← United States · All US Insider Profiles
US INSIDER PROFILE · NON-SCORING RESEARCH
Titterton Lewis H jr
Director
Identity: SEC reporting-owner CIK · Reporting-owner CIK: 0001499254
Purchase history
- Companies traded
- 2
- Purchases · 12M
- 6
- Purchases · 24M
- 12
- Average purchase
- $111.3K
- Median purchase
- $26.5K
- Gross purchase value
- $1.3M
Companies: Anixa Biosciences Inc | PARKERVISION INC
12 SEC accession(s) · 0 joint-owner event(s). Values are reported Form 4 transaction values in USD.
Qualifying purchase disclosures
| Published | Company | Ticker | Role | Reported value | SEC source |
|---|---|---|---|---|---|
| 2026-09-25 | Anixa Biosciences Inc | ANIX | Director | $131.9K | Open filing |
| 2026-09-14 | Anixa Biosciences Inc | ANIX | Director | $27.3K | Open filing |
| 2026-07-20 | Anixa Biosciences Inc | ANIX | Director | $41.6K | Open filing |
| 2026-07-16 | Anixa Biosciences Inc | ANIX | Director | $9.2K | Open filing |
| 2026-06-17 | Anixa Biosciences Inc | ANIX | Director | $7.5K | Open filing |
| 2025-11-18 | PARKERVISION INC | PRKR | Director | $1.0M | Open filing |
| 2025-08-04 | Anixa Biosciences Inc | ANIX | Director | $30.8K | Open filing |
| 2025-07-15 | Anixa Biosciences Inc | ANIX | Director | $31.4K | Open filing |
| 2025-01-27 | Anixa Biosciences Inc | ANIX | Director | $8.8K | Open filing |
| 2025-01-23 | Anixa Biosciences Inc | ANIX | Director | $6.0K | Open filing |
| 2025-01-22 | Anixa Biosciences Inc | ANIX | Director | $15.5K | Open filing |
| 2025-01-17 | Anixa Biosciences Inc | ANIX | Director | $25.7K | Open filing |
Post-purchase outcomes
Excess return = stock return − S&P 500 ETF (SPY adjusted close) return. Returns start on the first shared trading session on or after publication.
| Period | Completed events | Price coverage | Hit rate | Median excess return | Average excess return | Worst excess return |
|---|---|---|---|---|---|---|
| 5D | 11Developing | 91.7% (11/12) | 72.7% (8/11) | +1.4% | +2.3% | -10.6% |
| 20D | 10Developing | 90.9% (10/11) | 50.0% (5/10) | +2.3% | +4.2% | -8.3% |
| 60D | 9Developing | 90.0% (9/10) | 77.8% (7/9) | +7.6% | +6.2% | -27.9% |
| 120D | 6Developing | 85.7% (6/7) | 66.7% (4/6) | +10.2% | +6.4% | -15.6% |
Research patterns
- First purchase in 12M
- 1/11
- Large purchase ≥ $100k
- 2/12
- Cluster buying · 15D
- 11/12
- Buying the dip
- 10/11
Routine / opportunistic: Not classifiable. These labels never affect the score or ranking.
Small samples remain visible but are not scored. This research enrichment never affects US-v1.1.